ANN ARBOR, MI – A groundbreaking study from the University of Michigan Health has shed new light on the complex relationship between commonly used psychoactive substances and symptom management in individuals living with multiple sclerosis (MS). The research reveals that while substances like caffeine, alcohol, nicotine, cannabis, and opioids may offer fleeting relief for specific MS symptoms, they often come with an unexpected trade-off, exacerbating other crucial aspects of well-being such as fatigue, pain, stress, or depressive symptoms.
This revelation underscores a critical need for both patients and healthcare providers to engage in open, informed dialogue about the pervasive practice of self-medication within the MS community. The study’s findings, published in the Archive of Physical Medicine and Rehabilitation, challenge simplistic views of symptom relief, highlighting the nuanced and often contradictory effects these substances can have on a daily basis.
Main Facts: A Deeper Look into Daily Realities
The core finding of the study is that psychoactive substances, frequently employed for recreational, social, or self-management purposes by people with MS, exhibit a "mixed effects" profile. This means that immediate, desired benefits—such as a temporary reduction in pain or a boost in alertness—are often accompanied by the unwelcome intensification of other symptoms shortly thereafter. For instance, a substance taken to combat fatigue might inadvertently elevate stress levels, or one used for pain relief could worsen feelings of depression.
Dr. Anna Kratz, PhD, a professor of Physical Medicine and Rehabilitation at University of Michigan Health and head of the Kratz Lab, spearheaded this investigation. Her team recognized that while the use of these substances is common, a detailed, real-time understanding of their dynamic impact on MS symptoms was largely absent. Traditional retrospective studies often fail to capture the immediate, fluctuating nature of symptom experience and substance effects.
The study specifically examined the daily usage patterns of alcohol, caffeine, nicotine, cannabis, and opioids, correlating their consumption with real-time reports of fatigue, pain, stress, and depressive symptoms among participants with MS. The resulting data painted a picture of intricate, often counterintuitive, interactions between substance use and symptom severity.
Key Takeaways:
- Psychoactive substances commonly used by people with MS—including alcohol, caffeine, nicotine, cannabis, and opioids—often have mixed effects on symptoms.
- Immediate relief for one symptom may lead to the worsening of others, such as increased fatigue, pain, stress, or depressive symptoms.
- The study utilized an innovative ecological momentary assessment (EMA) approach, capturing real-time symptom severity and substance use four times a day for 14 days.
- The findings emphasize the importance of self-reflection for patients regarding their substance use and its actual impact on their well-being.
- Healthcare providers are urged to initiate open and non-judgmental conversations with patients about psychoactive substance use to offer better, personalized guidance.
Chronology: Tracing the Research Journey
The genesis of this study lies in the observed prevalence of psychoactive substance use among individuals managing chronic conditions like MS. Dr. Kratz and her team recognized that while general population data existed, the specific context of MS—a complex neurological disorder characterized by a wide array of fluctuating and often debilitating symptoms—warranted a dedicated and nuanced investigation.
The research team at the University of Michigan Health, collaborating with colleagues from the University of Washington and Wayne State University, embarked on a mission to gather more precise data. Their objective was not to condemn or endorse substance use, but to understand its genuine, lived impact. Traditional research methodologies, often relying on participants’ recall over weeks or months, are notoriously susceptible to memory bias, especially when dealing with fluctuating symptoms and habits. This limitation spurred the adoption of a more innovative and accurate approach.
The study design centered around an ecological momentary assessment (EMA). This method is a form of real-time data collection that minimizes recall bias by prompting participants to report on their experiences in their natural environments as they happen. For this study, participants with MS were instructed to report on their symptom severity and substance use four times a day over a two-week period (14 days). This intensive data collection window, spanning multiple daily check-ins, provided a rich, granular dataset reflecting the immediate temporal associations between substance consumption and symptom fluctuations.
Once the data was collected, the research team meticulously analyzed the patterns. By integrating the momentary symptom ratings (fatigue, pain, stress, depressive symptoms) with self-reported information on the prior use of alcohol, caffeine, nicotine, cannabis, or opioids, they began to identify the intricate and often bidirectional relationships. This careful, real-time tracking allowed them to move beyond anecdotal observations and generate evidence-based correlations, ultimately leading to the publication of their findings in the esteemed Archive of Physical Medicine and Rehabilitation. The publication marks a significant step in providing concrete data to inform clinical discussions and patient self-management strategies.
Supporting Data: The Power of Real-Time Assessment
The strength of this study lies fundamentally in its methodological rigor, particularly the application of the ecological momentary assessment (EMA). Unlike conventional survey methods that ask participants to recall their experiences over extended periods, EMA captures data in real-time, offering an unparalleled window into the dynamic interplay between daily behaviors and symptom manifestation.
Imagine trying to remember how a cup of coffee affected your fatigue and stress levels a week ago, or how a pain medication influenced your mood two days prior. Such recollections are often inaccurate, influenced by current mood, memory distortions, and the general tendency to simplify complex experiences. EMA circumvents these issues entirely. By prompting participants four times a day for 14 consecutive days, the study generated a vast number of data points—hundreds per participant—providing a high-resolution snapshot of their lived experience.
Participants were asked to use a simple, accessible method (likely a smartphone app or similar digital tool) to log their current levels of:
- Fatigue: A common and often debilitating symptom of MS.
- Pain: Another prevalent and challenging symptom.
- Stress: Both a symptom and a potential trigger or exacerbator of other MS symptoms.
- Depressive symptoms: A significant comorbidity in MS, impacting quality of life.
Crucially, alongside these symptom ratings, they also reported whether they had used alcohol, caffeine, nicotine, cannabis, or opioids prior to that specific rating period. This direct temporal link was vital for identifying immediate associations. The research team then employed sophisticated statistical analyses to uncover patterns within this dense dataset. While the original summary does not list the specific correlations for each substance and symptom combination, it unequivocally states that the study found "mixed positive and negative effects for several substances." This implies that for a given substance, participants might experience a temporary alleviation of one symptom (e.g., caffeine reducing fatigue) while simultaneously reporting an increase in another (e.g., caffeine increasing stress or anxiety). Similarly, alcohol might temporarily dull pain but could lead to increased fatigue or depressive symptoms later.
This "mixed effects" finding is the critical takeaway. It moves beyond a simple "good" or "bad" classification, revealing the intricate and often contradictory impact of these substances within the highly variable context of MS. The detailed methodology ensured that these findings are not merely anecdotal but are grounded in systematically collected, real-time empirical evidence.
Official Responses: A Call for Dialogue and Understanding
Dr. Anna Kratz’s insights provide the vital human element and practical implications of the study. Her statements emphasize both the commonality of self-medication and the profound responsibility of healthcare providers to engage with this reality.
"Just as many people look to a cup of coffee in the afternoon for a pick me up, people with multiple sclerosis may seek caffeine to help with fatigue or alcohol to manage pain," Dr. Kratz explained. This analogy normalizes the behavior, framing it not as an anomaly but as a natural human response to discomfort and a desire for relief. It acknowledges that individuals with MS are often trying to cope with relentless symptoms in the best way they know how, using readily available substances that are socially acceptable or easily accessible.
However, Dr. Kratz quickly pivots to the crucial message for patients: "Insights from studies like this could prompt a person with multiple sclerosis to reflect on what they are putting into their bodies and how it is impacting their symptoms." This highlights the importance of self-awareness and critical evaluation. The study’s findings are not prescriptive; rather, they are designed to empower patients with knowledge, encouraging them to observe their own patterns of substance use and its actual, real-time effects, rather than relying on perceived benefits or habitual consumption. This self-reflection is the first step towards making more informed choices that align with their overall well-being.
Beyond patient self-reflection, Dr. Kratz issued a strong call to action for healthcare providers. She encourages them "not only to talk with their provider about what outside psychoactive substances they are using habitually or for recreation or symptom management, but for providers to be attentive listeners as well." This underscores a critical gap in current clinical practice. Patients often hesitate to disclose substance use due to fear of judgment, while providers might not routinely inquire or feel equipped to discuss these sensitive topics.
Dr. Kratz argues that this dynamic must change. "Having a better understanding of how these substances impact patients with multiple sclerosis will be beneficial for providers," she stated. This knowledge allows providers to move beyond a dismissive or punitive stance. Instead, armed with a nuanced understanding of potential pros and cons, they can engage in empathetic, evidence-based conversations.
"Patients using psychoactive substances is not going to go away," Dr. Kratz affirmed, acknowledging the enduring nature of this behavior. "Being able to understand the role these substances play and the pros and cons of each will allow providers to better advise their patients when it comes to use of these products." This is a paradigm shift: from attempting to prevent or forbid, to educating and guiding. It recognizes patient autonomy while offering expert, informed support, ultimately leading to more comprehensive and patient-centered care.
Implications: Reshaping Patient Self-Management and Clinical Guidance
The implications of this study are far-reaching, impacting both the individual living with MS and the broader healthcare system tasked with their care.
For Patients with Multiple Sclerosis:
The primary implication for individuals with MS is the call for enhanced self-awareness and critical evaluation of their daily habits. The "mixed effects" finding serves as a powerful prompt for introspection. If a person uses caffeine for fatigue, they might now be encouraged to observe if it simultaneously heightens their stress or anxiety. If alcohol temporarily dulls pain, they might be prompted to consider if it contributes to next-day fatigue or worsens depressive symptoms. This level of granular, real-time self-monitoring, perhaps even inspired by the study’s EMA methodology, can empower patients to make more conscious choices. It encourages them to move beyond habitual use driven by immediate gratification and towards a more holistic assessment of overall well-being. The study doesn’t demonize substance use but advocates for informed use, aligning with the complex and often unpredictable nature of MS itself. It also reinforces the message that while self-management is crucial, it should ideally be a collaborative effort with medical professionals.
For Healthcare Providers and Clinical Practice:
The study presents a clear mandate for healthcare providers: integrate discussions about psychoactive substance use into routine MS care. Historically, these conversations have often been avoided or approached with a judgmental tone, leading to patient non-disclosure. Dr. Kratz’s work suggests that a non-judgmental, inquisitive approach is not only more ethical but also more effective. Providers need to be "attentive listeners," understanding the motivations behind self-medication—the often desperate search for relief from unrelenting symptoms.
Armed with the knowledge that these substances have mixed effects, providers can offer more nuanced advice. Instead of simply advising against a substance, they can discuss the potential trade-offs, helping patients weigh immediate benefits against potential long-term or concurrent drawbacks. This could involve:
- Screening: Routinely asking about the use of alcohol, caffeine, nicotine, cannabis, and other substances.
- Education: Providing clear, evidence-based information on the known and potential effects of these substances in the context of MS.
- Personalized Guidance: Collaborating with patients to identify patterns, explore alternatives, or adjust use strategies based on individual symptom profiles and goals.
- Referrals: Connecting patients to appropriate resources for substance use management, mental health support, or alternative symptom therapies if needed.
The study also underscores the importance of a holistic approach to MS management, recognizing that symptoms like fatigue, pain, stress, and depression are interconnected. Addressing one symptom through substance use without considering its impact on others is often counterproductive.
Broader Context: Self-Medication in Chronic Illness
The findings resonate beyond MS, touching upon the broader phenomenon of self-medication in chronic illness. Individuals facing persistent, often debilitating symptoms for which conventional treatments may offer incomplete relief, frequently turn to accessible substances to cope. This study provides a template for understanding the complex dynamics of such practices, urging a compassionate yet evidence-based approach across various chronic conditions. It highlights the ingenuity and resilience of patients in managing their conditions, but also the potential pitfalls of unguided self-treatment.
Future Research Directions:
This study opens numerous avenues for future research.
- Specific Correlations: While the study identified mixed effects, future research could delve deeper into the specific correlations for each substance with each symptom, providing more granular data.
- Long-Term Effects: The 14-day EMA provides excellent real-time data, but longer-term studies are needed to understand the cumulative effects of chronic substance use on MS progression, overall health, and quality of life.
- Mechanism of Action: Investigating the biological mechanisms through which these substances exert their mixed effects in the MS brain and body.
- Intervention Studies: Developing and testing interventions designed to help patients manage symptoms more effectively, reduce reliance on substances with negative trade-offs, or provide safer alternatives.
- Patient Education Tools: Creating resources and tools based on these findings to empower patients with MS to better track and understand their own substance use patterns and symptoms.
- Provider Training: Developing curricula and training programs for healthcare providers to enhance their skills in discussing substance use with chronic illness patients.
Conclusion: Towards Informed Empowerment
The University of Michigan Health study offers a pivotal contribution to understanding the nuanced challenges faced by individuals with multiple sclerosis. By employing an innovative real-time assessment methodology, it has illuminated the often-hidden complexities of psychoactive substance use in symptom management. The discovery of "mixed effects"—where immediate relief for one symptom may come at the cost of exacerbating another—is a crucial insight that demands attention.
This research is not a judgment but an invitation: for patients, an invitation to greater self-awareness and critical reflection on their coping strategies; for healthcare providers, an invitation to engage in more empathetic, informed, and proactive dialogue. As Dr. Kratz aptly notes, patient use of psychoactive substances is a reality that will not disappear. The path forward lies in understanding, not avoidance, enabling a collaborative environment where patients feel empowered to discuss their challenges openly, and providers are equipped to offer guidance that is truly beneficial, personalized, and grounded in scientific evidence. Ultimately, this study paves the way for a more holistic, compassionate, and effective approach to managing the multifaceted burden of multiple sclerosis.
Additional authors: Jeeyeon Kim, from the Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI. Dawn M. Ehde, from the Department of Rehabilitation, University of Washington, Seattle, WA. Kevin N. Alschuler, from the Department of Rehabilitation Medicine University of Washington, Seattle, WA and the Department of Neurology, University of Washington, Seattle, WA. Nora E. Fritz, from the Department of Health Care Sciences, Wayne State University, Detroit, MI and the Department of Neurology, Wayne State University, Detroit, MI.
Paper Cited: “Daily Temporal Associations Between Use of Psychoactive Substances and Fatigue, Pain, Stress, and Depressive Symptoms in People With Multiple Sclerosis,” Archive of Physical Medicine and Rehabilitation. DOI: 10.1016/j.apmr.2026.01.014
Featured image: Dreamstime
